Comments for: Blood pressure drug too risky, panel says

Blood pressure drug too risky, panel says
WASHINGTON – An experimental blood pressure drug once heavily promoted by Bristol-Myers Squibb is too risky to be sold, government advisers said Friday. The recommendation is a serious blow to the drug, Vanlev. Bristol-Myers had stoked expectations that Vanlev would become one of its next… Read More
      Read more

      You may also like

      By continuing to use this site, you give your consent to our use of cookies for analytics, personalization and ads. Learn more.